<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01390909</url>
  </required_header>
  <id_info>
    <org_study_id>113917</org_study_id>
    <nct_id>NCT01390909</nct_id>
  </id_info>
  <brief_title>Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database</brief_title>
  <official_title>Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antiepileptic drugs (AEDs) are the main therapeutic option for patients with epilepsy;
      however, complete seizure control remains elusive for many patients. Uncontrolled or
      refractory epilepsy is associated with a higher risk of mortality, physical injuries, and
      depression or anxiety compared with patients with controlled epilepsy. Higher resource
      utilization for patients with poor control is likely to be associated with higher economic
      costs. While diagnostic criteria for uncontrolled epilepsy are debated by neurologists,
      recent studies suggest that a diagnosis of uncontrolled epilepsy requires 1.) at least one
      seizure per month and 2.) a history of drug failures.

      The objective of this study is to identify patients with uncontrolled epilepsy in both a
      Medicaid database and a private health plan database, to describe patient characteristics and
      AED treatment patterns between cohorts of patients with uncontrolled versus well-controlled
      epilepsy, and to evaluate the economic burden of uncontrolled versus well-controlled
      epilepsy.

      For this evaluation, the data sources are medical and pharmacy claims in Medicaid databases
      from Florida (Third quarter 1997 to second quarter 2008), Iowa (First quarter 1998 to second
      quarter 2006), Kansas (First quarter 2001 to second quarter 2009), Missouri (First quarter
      1997 to second quarter 2008) and New Jersey (First quarter 1997 to fourth quarter 2008) and
      medical and pharmacy claims in an private health plan database.

      The study design is a retrospective, longitudinal, matched-cohort study. Eligible patient
      records will be assigned to one of three mutually-exclusive cohorts: uncontrolled epilepsy
      (at least 2 consecutive changes in AED therapy in at least 30 days, and at least 1
      epilepsy-related inpatient or emergency department (ED) visit within 365 days),
      well-controlled epilepsy (no AED changes and no epilepsy-related inpatient or ED visits), and
      intermediate epilepsy (not classified as uncontrolled or well-controlled).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Average Annualized Costs</measure>
    <time_frame>1 year</time_frame>
    <description>Average annualized overall healthcare costs and epilepsy-related healthcare costs were calculated for each treatment group. Epilepsy-related costs were those with a code for epilepsy. ED, Emergency Department; AMC, All Medical Costs; Ep Rel, Epilepsy Related. United States dollars were consumer price index adjusted for 2009.</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Actual">12386</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Medicaid patients with uncontrolled epilepsy</arm_group_label>
    <description>Database records for patients with 2 or more consecutive changes in anti-epileptic drug (AED) therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or emergency department (ED) visits within the 365 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medicaid patients with well-controlled epilepsy</arm_group_label>
    <description>Database records for patients with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medicaid patients with intermediate epilepsy</arm_group_label>
    <description>Database records for patients who are not classified as uncontrolled or well-controlled</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients in a private health plan with uncontrolled epilepsy</arm_group_label>
    <description>Database records for patients with 2 or more consecutive changes in AED therapy occuring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visits within 365 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients in a private health plan with well-controlled epileps</arm_group_label>
    <description>Database records for patients with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients in a private health plan with intermediate epilepsy</arm_group_label>
    <description>Database records for patients who are not classified as uncontrolled or well-controlled</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-epileptic drug (AED)</intervention_name>
    <description>Prescription claim for at least one AED including lamotrigine, tiagabine, pregabalin, ethosuximide, lacosamide, phenytoin, carbamazepine, valproic acid, felbamate, levetiracetam, zonisamide, primidone, oxcarbazepine, vigabatrin, phenobarbital, gabapentin, topiramate.</description>
    <arm_group_label>Patients in a private health plan with uncontrolled epilepsy</arm_group_label>
    <arm_group_label>Medicaid patients with intermediate epilepsy</arm_group_label>
    <arm_group_label>Patients in a private health plan with intermediate epilepsy</arm_group_label>
    <arm_group_label>Patients in a private health plan with well-controlled epileps</arm_group_label>
    <arm_group_label>Medicaid patients with uncontrolled epilepsy</arm_group_label>
    <arm_group_label>Medicaid patients with well-controlled epilepsy</arm_group_label>
    <other_name>Mysoline® is a registered trademark of Valeant Pharmaceuticals</other_name>
    <other_name>Neurotin® is registered trademark of Pfizer</other_name>
    <other_name>Inc</other_name>
    <other_name>Vimpat® is a registered trademark of UCB Pharma</other_name>
    <other_name>Tegretol® is a registered trademark of Novartis Pharmaceuticals</other_name>
    <other_name>Trileptal® is a registered trademark of Novartis Pharmaceuticals</other_name>
    <other_name>Sabril® is a registered trademark of Lundbeck Inc</other_name>
    <other_name>Felbatol® is a registered trademark of MedPointe</other_name>
    <other_name>Topamax® is a registered trademark of Ortho-McNeill-Janssen Pharmaceuticals</other_name>
    <other_name>Depakote® is a registered trademark of Abbott Laboratories</other_name>
    <other_name>Zonegran® is a registered trademark of Dainippon Pharmaceutical C. Ltd.</other_name>
    <other_name>Gabatril® is a registered trademark of Cephalon</other_name>
    <other_name>Keppra® is registered trademark of UCB Pharma</other_name>
    <other_name>Zarontin® is a registered trademark of Pfizer</other_name>
    <other_name>Lamictal® is a registered trademark of GlaxoSmithKline</other_name>
    <other_name>Luminal® is a registered trademark of Abbott Laboratories</other_name>
    <other_name>Dilantin® is a registered trademark of Pfizer</other_name>
    <other_name>Lyrica is registered trademark of Pfizer</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The electronic records from adult patients with epilepsy who are enrolled in Medicaid in
        Florida, Iowa, Kansas, Missouri or New Jersey or in a private health plan database. Patient
        records will be classified into one of three mutually-exclusive cohorts: uncontrolled
        epilepsy, well-controlled epilepsy, and intermediate epilepsy (not classified as
        uncontrolled or well-controlled).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age at the initiation of anti-epileptic drug (AED) treatment as
             noted in the database

          -  A record of at least one medical visit with a diagnosis of epilepsy (ICD-9-CM 345.xx)
             or at least two diagnoses of non-febrile convulsions (ICD-9-CM 780.30 or 780.39)
             occuring more than 30 days apart

          -  At least one pharmacy claim for an anti-epileptic drug (AED)

          -  Continuous enrollment throughout the observation period (minimum of 365 days).
             Patients with gaps in Medicaid enrollment will be observed only during their period of
             continuous enrollment, provided that all the above criteria are met

        Exclusion Criteria:

          -  Age less than 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2011</study_first_submitted>
  <study_first_submitted_qc>July 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2011</study_first_posted>
  <results_first_submitted>October 13, 2011</results_first_submitted>
  <results_first_submitted_qc>January 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 14, 2012</results_first_posted>
  <last_update_submitted>October 4, 2012</last_update_submitted>
  <last_update_submitted_qc>October 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>epilepsy</keyword>
  <keyword>anti-epileptic drug</keyword>
  <keyword>polytherapy</keyword>
  <keyword>adherence</keyword>
  <keyword>Medicaid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactitol</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Medicaid, Well Controlled</title>
          <description>Database records for participants with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits</description>
        </group>
        <group group_id="P2">
          <title>Medicaid, Uncontrolled</title>
          <description>Database records for participants with 2 or more consecutive changes in AED therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visits within the next 365 days. This arm represents all participant records that met the criteria for uncontrolled epilepsy. Participants in the Medicaid, Uncontrolled, Subgroup were matched with participant records in the Medicaid, well-controlled cohort.</description>
        </group>
        <group group_id="P3">
          <title>Medicaid, Intermediate</title>
          <description>Database records for participants who are not classified as uncontrolled or well controlled</description>
        </group>
        <group group_id="P4">
          <title>Private, Well Controlled</title>
          <description>Database records for participants with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visit</description>
        </group>
        <group group_id="P5">
          <title>Private, Uncontrolled</title>
          <description>Database records for participants with 2 or more consecutive changes in AED therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visit within the next 365 days. This arm represents all participant records that met the criteria for uncontrolled epilepsy. Participants in the Medicaid, Uncontrolled, Subgroup were matched with participant records in the Medicaid, well-controlled cohort.</description>
        </group>
        <group group_id="P6">
          <title>Private, Intermediate</title>
          <description>Database records for participants who are not classified as uncontrolled or well controlled</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3454"/>
                <participants group_id="P2" count="3552"/>
                <participants group_id="P3" count="3552"/>
                <participants group_id="P4" count="602"/>
                <participants group_id="P5" count="613"/>
                <participants group_id="P6" count="613"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants in Subgroup</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3454"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="602"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3454"/>
                <participants group_id="P2" count="3552"/>
                <participants group_id="P3" count="3552"/>
                <participants group_id="P4" count="602"/>
                <participants group_id="P5" count="613"/>
                <participants group_id="P6" count="613"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Medicaid, Well Controlled</title>
          <description>Database records for participants with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits</description>
        </group>
        <group group_id="B2">
          <title>Medicaid, Uncontrolled</title>
          <description>Database records for participants with 2 or more consecutive changes in AED therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visits within the next 365 days. This arm represents all participant records that met the criteria for uncontrolled epilepsy. Participants in the Medicaid, Uncontrolled, Subgroup (3454 participants) were matched with participant records in the Medicaid, well-controlled cohort.</description>
        </group>
        <group group_id="B3">
          <title>Medicaid, Intermediate</title>
          <description>Database records for participants who are not classified as uncontrolled or well controlled</description>
        </group>
        <group group_id="B4">
          <title>Private, Well Controlled</title>
          <description>Database records for participants with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits</description>
        </group>
        <group group_id="B5">
          <title>Private, Uncontrolled</title>
          <description>Database records for participants with 2 or more consecutive changes in AED therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visits within the next 365 days. This arm represents all participant records that met the criteria for uncontrolled epilepsy. Participants in the Medicaid, Uncontrolled, Subgroup (602 participants) were matched with participant records in the Medicaid, well-controlled cohort.</description>
        </group>
        <group group_id="B6">
          <title>Private, Intermediate</title>
          <description>Database records for participants who are not classified as uncontrolled or well controlled</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3454"/>
            <count group_id="B2" value="3552"/>
            <count group_id="B3" value="3552"/>
            <count group_id="B4" value="602"/>
            <count group_id="B5" value="613"/>
            <count group_id="B6" value="613"/>
            <count group_id="B7" value="12386"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>For the total population and the subgroup total population, a weighted average of the individual study group means and number of participants was used. The standard deviation (SD) is the SD of the study group means.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Overall Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.5" spread="15.4"/>
                    <measurement group_id="B2" value="41.3" spread="14.1"/>
                    <measurement group_id="B3" value="41.2" spread="14.6"/>
                    <measurement group_id="B4" value="54.2" spread="17.1"/>
                    <measurement group_id="B5" value="54.1" spread="17.3"/>
                    <measurement group_id="B6" value="54.6" spread="16.7"/>
                    <measurement group_id="B7" value="43.2" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B2" value="41.4" spread="14.2"/>
                    <measurement group_id="B3" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B4" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B5" value="54.0" spread="17.4"/>
                    <measurement group_id="B6" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B7" value="43.3" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female, Overall Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2106"/>
                    <measurement group_id="B2" value="2171"/>
                    <measurement group_id="B3" value="2159"/>
                    <measurement group_id="B4" value="341"/>
                    <measurement group_id="B5" value="351"/>
                    <measurement group_id="B6" value="332"/>
                    <measurement group_id="B7" value="7460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male, Overall Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1348"/>
                    <measurement group_id="B2" value="1381"/>
                    <measurement group_id="B3" value="1393"/>
                    <measurement group_id="B4" value="261"/>
                    <measurement group_id="B5" value="262"/>
                    <measurement group_id="B6" value="281"/>
                    <measurement group_id="B7" value="4926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female, Subgroup</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B2" value="2091"/>
                    <measurement group_id="B3" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B4" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B5" value="345"/>
                    <measurement group_id="B6" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B7" value="2436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male, Subgroup</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B2" value="345"/>
                    <measurement group_id="B3" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B4" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B5" value="257"/>
                    <measurement group_id="B6" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B7" value="602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Days of Observation</title>
          <description>For the total population and subgroups, a weighted average of the individual study group means and number of participants was used. The SDs reflect the SDs of the study group means.</description>
          <units>days of observation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Overall Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2184" spread="1181"/>
                    <measurement group_id="B2" value="2296" spread="1132"/>
                    <measurement group_id="B3" value="2502" spread="1124"/>
                    <measurement group_id="B4" value="1572" spread="847"/>
                    <measurement group_id="B5" value="1478" spread="749"/>
                    <measurement group_id="B6" value="1739" spread="792"/>
                    <measurement group_id="B7" value="2221" spread="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B2" value="2290" spread="1133"/>
                    <measurement group_id="B3" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B4" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B5" value="1485" spread="751"/>
                    <measurement group_id="B6" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B7" value="2170.5" spread="402.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Charlson Comorbidity Index (CCI) Scores</title>
          <description>The Charlson Comorbidity Index estimates 10-year mortality risk. Scores range from 0 - 37, with a lower score indicating a higher chance of survival. For the total population and the subgroup, a weighted average of the study group means was used. The standard deviation (SD) is the SD of the study group means.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Overall Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.98" spread="1.83"/>
                    <measurement group_id="B2" value="1.09" spread="1.84"/>
                    <measurement group_id="B3" value="1.00" spread="1.78"/>
                    <measurement group_id="B4" value="1.13" spread="1.65"/>
                    <measurement group_id="B5" value="1.32" spread="1.91"/>
                    <measurement group_id="B6" value="1.20" spread="1.82"/>
                    <measurement group_id="B7" value="1.05" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroup</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B2" value="1.08" spread="1.83"/>
                    <measurement group_id="B3" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B4" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B5" value="1.29" spread="1.88"/>
                    <measurement group_id="B6" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B7" value="1.11" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participant records with diagnosis codes for the indicated diseases or disorders</title>
          <units>participant records</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Alzheimer’s Disease, Overall Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alzheimer's Disease Subgroup</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B4" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B7" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brain Tumor, Overall Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="50"/>
                    <measurement group_id="B6" value="43"/>
                    <measurement group_id="B7" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brain Tumor, Subgroup</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B4" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B7" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis, Overall Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis, Subgroup</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B4" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B7" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Migraine, Overall Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="262"/>
                    <measurement group_id="B3" value="262"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="42"/>
                    <measurement group_id="B6" value="35"/>
                    <measurement group_id="B7" value="840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Migraine, Subgroup</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B2" value="239"/>
                    <measurement group_id="B3" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B4" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B7" value="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke, Overall Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="267"/>
                    <measurement group_id="B2" value="303"/>
                    <measurement group_id="B3" value="264"/>
                    <measurement group_id="B4" value="123"/>
                    <measurement group_id="B5" value="134"/>
                    <measurement group_id="B6" value="154"/>
                    <measurement group_id="B7" value="1245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke, Subgroup</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B2" value="302"/>
                    <measurement group_id="B3" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B4" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B5" value="128"/>
                    <measurement group_id="B6" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B7" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety Disorders, Overall Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="356"/>
                    <measurement group_id="B2" value="447"/>
                    <measurement group_id="B3" value="440"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="28"/>
                    <measurement group_id="B7" value="1344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety Disorders, Subgroup</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B2" value="410"/>
                    <measurement group_id="B3" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B4" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B5" value="38"/>
                    <measurement group_id="B6" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B7" value="448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bipolar Disorder, Overall Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="428"/>
                    <measurement group_id="B2" value="439"/>
                    <measurement group_id="B3" value="472"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="1394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bipolar Disorder, Subgroup</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B2" value="397"/>
                    <measurement group_id="B3" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B4" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B7" value="414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression, Overall Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="821"/>
                    <measurement group_id="B2" value="890"/>
                    <measurement group_id="B3" value="897"/>
                    <measurement group_id="B4" value="90"/>
                    <measurement group_id="B5" value="95"/>
                    <measurement group_id="B6" value="102"/>
                    <measurement group_id="B7" value="2895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression, Subgroup</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B2" value="833"/>
                    <measurement group_id="B3" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B4" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B5" value="90"/>
                    <measurement group_id="B6" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B7" value="923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychosis, Overall Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="809"/>
                    <measurement group_id="B2" value="794"/>
                    <measurement group_id="B3" value="816"/>
                    <measurement group_id="B4" value="62"/>
                    <measurement group_id="B5" value="65"/>
                    <measurement group_id="B6" value="65"/>
                    <measurement group_id="B7" value="2611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychosis, Subgroup</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B2" value="754"/>
                    <measurement group_id="B3" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B4" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B5" value="65"/>
                    <measurement group_id="B6" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B7" value="819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Personality Disorder, Overall Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="951"/>
                    <measurement group_id="B2" value="1062"/>
                    <measurement group_id="B3" value="1024"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="68"/>
                    <measurement group_id="B6" value="58"/>
                    <measurement group_id="B7" value="3214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Personality Disorder, Subgroup</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B2" value="1001"/>
                    <measurement group_id="B3" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B4" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B5" value="67"/>
                    <measurement group_id="B6" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B7" value="1068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Retardation, Overall Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="482"/>
                    <measurement group_id="B2" value="322"/>
                    <measurement group_id="B3" value="434"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="1262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Retardation, Subgroup</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B2" value="312"/>
                    <measurement group_id="B3" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B4" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="NA">There are no subgroup participants.</measurement>
                    <measurement group_id="B7" value="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Annualized Costs</title>
        <description>Average annualized overall healthcare costs and epilepsy-related healthcare costs were calculated for each treatment group. Epilepsy-related costs were those with a code for epilepsy. ED, Emergency Department; AMC, All Medical Costs; Ep Rel, Epilepsy Related. United States dollars were consumer price index adjusted for 2009.</description>
        <time_frame>1 year</time_frame>
        <population>For Arms 1 - 4, Medicaid-enrolled participants with uncontrolled epilepsy (see Arm Descriptions for Arm Title 1 and Arm Title 3) or matched participants with well-controlled or intermediate epilepsy. For Arms 5 - 8, privately-insured participants with uncontrolled epilepsy or matched participants with well-controlled or intermediate epilepsy.</population>
        <group_list>
          <group group_id="O1">
            <title>Medicaid, Uncontrolled, Subgroup</title>
            <description>Database records for participants with 2 or more consecutive changes in anti-epileptic drug (AED) therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or emergency department (ED) visits within the next 365 days. This subgroup was matched with participant records in the Medicaid, well-controlled cohort</description>
          </group>
          <group group_id="O2">
            <title>Medicaid, Well Controlled</title>
            <description>Database records for participants with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits</description>
          </group>
          <group group_id="O3">
            <title>Medicaid, Uncontrolled</title>
            <description>Database records for participants with 2 or more consecutive changes in AED therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visits within the next 365 days. This arm represents all participant records that met the criteria for uncontrolled epilepsy</description>
          </group>
          <group group_id="O4">
            <title>Medicaid, Intermediate</title>
            <description>Database records for participants who are not classified as uncontrolled or well controlled</description>
          </group>
          <group group_id="O5">
            <title>Private, Uncontrolled, Subgroup</title>
            <description>Database records for participants with 2 or more consecutive changes in AED therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visit within the next 365 days. This subgroup was matched with participant records in the private, well-controlled cohort.</description>
          </group>
          <group group_id="O6">
            <title>Private, Well Controlled</title>
            <description>Database records for participants with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visit</description>
          </group>
          <group group_id="O7">
            <title>Private, Uncontrolled</title>
            <description>Database records for participants with 2 or more consecutive changes in AED therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visit within the next 365 days. This arm represents all participant records that met the criteria for uncontrolled epilepsy.</description>
          </group>
          <group group_id="O8">
            <title>Private, Intermediate</title>
            <description>Database records for participants who are not classified as uncontrolled or well controlled</description>
          </group>
        </group_list>
        <measure>
          <title>Average Annualized Costs</title>
          <description>Average annualized overall healthcare costs and epilepsy-related healthcare costs were calculated for each treatment group. Epilepsy-related costs were those with a code for epilepsy. ED, Emergency Department; AMC, All Medical Costs; Ep Rel, Epilepsy Related. United States dollars were consumer price index adjusted for 2009.</description>
          <population>For Arms 1 - 4, Medicaid-enrolled participants with uncontrolled epilepsy (see Arm Descriptions for Arm Title 1 and Arm Title 3) or matched participants with well-controlled or intermediate epilepsy. For Arms 5 - 8, privately-insured participants with uncontrolled epilepsy or matched participants with well-controlled or intermediate epilepsy.</population>
          <units>United States dollars</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3454"/>
                <count group_id="O2" value="3454"/>
                <count group_id="O3" value="3552"/>
                <count group_id="O4" value="3552"/>
                <count group_id="O5" value="602"/>
                <count group_id="O6" value="602"/>
                <count group_id="O7" value="613"/>
                <count group_id="O8" value="613"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEDs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1352" spread="4580"/>
                    <measurement group_id="O2" value="462" spread="2072"/>
                    <measurement group_id="O3" value="1357" spread="4590"/>
                    <measurement group_id="O4" value="1050" spread="4297"/>
                    <measurement group_id="O5" value="1697" spread="3979"/>
                    <measurement group_id="O6" value="639" spread="2248"/>
                    <measurement group_id="O7" value="1713" spread="3989"/>
                    <measurement group_id="O8" value="1299" spread="3949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-AEDs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5615" spread="15730"/>
                    <measurement group_id="O2" value="3657" spread="11702"/>
                    <measurement group_id="O3" value="5725" spread="16016"/>
                    <measurement group_id="O4" value="4801" spread="15357"/>
                    <measurement group_id="O5" value="4497" spread="11374"/>
                    <measurement group_id="O6" value="3096" spread="10692"/>
                    <measurement group_id="O7" value="4587" spread="11972"/>
                    <measurement group_id="O8" value="3883" spread="9436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalizations; AMC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6902" spread="31181"/>
                    <measurement group_id="O2" value="958" spread="9518"/>
                    <measurement group_id="O3" value="7041" spread="31499"/>
                    <measurement group_id="O4" value="3513" spread="22265"/>
                    <measurement group_id="O5" value="11308" spread="62399"/>
                    <measurement group_id="O6" value="1697" spread="12292"/>
                    <measurement group_id="O7" value="12357" spread="84898"/>
                    <measurement group_id="O8" value="5858" spread="37310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ED Visits; AMC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400" spread="1496"/>
                    <measurement group_id="O2" value="97" spread="731"/>
                    <measurement group_id="O3" value="421" spread="1661"/>
                    <measurement group_id="O4" value="242" spread="1371"/>
                    <measurement group_id="O5" value="586" spread="4392"/>
                    <measurement group_id="O6" value="76" spread="804"/>
                    <measurement group_id="O7" value="603" spread="4422"/>
                    <measurement group_id="O8" value="254" spread="2898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outpatient Visits; AMC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2416" spread="11759"/>
                    <measurement group_id="O2" value="1258" spread="9953"/>
                    <measurement group_id="O3" value="2466" spread="11829"/>
                    <measurement group_id="O4" value="1804" spread="11649"/>
                    <measurement group_id="O5" value="5757" spread="24888"/>
                    <measurement group_id="O6" value="3061" spread="13353"/>
                    <measurement group_id="O7" value="5771" spread="24883"/>
                    <measurement group_id="O8" value="5780" spread="37154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurology Visits; AMC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" spread="850"/>
                    <measurement group_id="O2" value="21" spread="425"/>
                    <measurement group_id="O3" value="86" spread="839"/>
                    <measurement group_id="O4" value="52" spread="666"/>
                    <measurement group_id="O5" value="556" spread="4306"/>
                    <measurement group_id="O6" value="175" spread="1593"/>
                    <measurement group_id="O7" value="566" spread="4352"/>
                    <measurement group_id="O8" value="442" spread="4263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Healthcare Services; AMC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22022" spread="106033"/>
                    <measurement group_id="O2" value="23202" spread="103595"/>
                    <measurement group_id="O3" value="22113" spread="107291"/>
                    <measurement group_id="O4" value="23428" spread="119218"/>
                    <measurement group_id="O5" value="1008" spread="5428"/>
                    <measurement group_id="O6" value="436" spread="4444"/>
                    <measurement group_id="O7" value="1026" spread="5472"/>
                    <measurement group_id="O8" value="645" spread="3910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalizations; Ep Rel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4102" spread="19775"/>
                    <measurement group_id="O2" value="NA">None of the participants in this study arm incurred the indicated type of healthcare encounter during the study period.</measurement>
                    <measurement group_id="O3" value="4135" spread="19915"/>
                    <measurement group_id="O4" value="1702" spread="13344"/>
                    <measurement group_id="O5" value="6700" spread="48095"/>
                    <measurement group_id="O6" value="NA">None of the participants in this study arm incurred the indicated type of healthcare encounter during the study period.</measurement>
                    <measurement group_id="O7" value="7646" spread="70525"/>
                    <measurement group_id="O8" value="2413" spread="23487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ED Visits; Ep Rel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109" spread="610"/>
                    <measurement group_id="O2" value="NA">None of the participants in this study arm incurred the indicated type of healthcare encounter during the study period.</measurement>
                    <measurement group_id="O3" value="111" spread="616"/>
                    <measurement group_id="O4" value="46" spread="540"/>
                    <measurement group_id="O5" value="152" spread="972"/>
                    <measurement group_id="O6" value="NA">None of the participants in this study arm incurred the indicated type of healthcare encounter during the study period.</measurement>
                    <measurement group_id="O7" value="153" spread="968"/>
                    <measurement group_id="O8" value="39" spread="635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outpatient Visits; Ep Rel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="467" spread="2218"/>
                    <measurement group_id="O2" value="68" spread="490"/>
                    <measurement group_id="O3" value="469" spread="2239"/>
                    <measurement group_id="O4" value="248" spread="1660"/>
                    <measurement group_id="O5" value="703" spread="3072"/>
                    <measurement group_id="O6" value="179" spread="1042"/>
                    <measurement group_id="O7" value="702" spread="3082"/>
                    <measurement group_id="O8" value="479" spread="6624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurology Visits; Ep Rel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="712"/>
                    <measurement group_id="O2" value="9" spread="143"/>
                    <measurement group_id="O3" value="59" spread="703"/>
                    <measurement group_id="O4" value="33" spread="472"/>
                    <measurement group_id="O5" value="235" spread="1797"/>
                    <measurement group_id="O6" value="68" spread="577"/>
                    <measurement group_id="O7" value="237" spread="1845"/>
                    <measurement group_id="O8" value="165" spread="1670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Healthcare Costs; Ep Rel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1502" spread="14424"/>
                    <measurement group_id="O2" value="754" spread="10724"/>
                    <measurement group_id="O3" value="1475" spread="14265"/>
                    <measurement group_id="O4" value="1273" spread="14072"/>
                    <measurement group_id="O5" value="103" spread="752"/>
                    <measurement group_id="O6" value="17" spread="204"/>
                    <measurement group_id="O7" value="102" spread="746"/>
                    <measurement group_id="O8" value="42" spread="472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Healthcare Costs; AMC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38708" spread="114904"/>
                    <measurement group_id="O2" value="29635" spread="105644"/>
                    <measurement group_id="O3" value="39123" spread="116204"/>
                    <measurement group_id="O4" value="34839" spread="123866"/>
                    <measurement group_id="O5" value="24853" spread="81299"/>
                    <measurement group_id="O6" value="9005" spread="28038"/>
                    <measurement group_id="O7" value="26057" spread="100777"/>
                    <measurement group_id="O8" value="17719" spread="69241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Prescription Drug Costs, AEDs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>849</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>786</ci_lower_limit>
            <ci_upper_limit>921</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Prescription Drug Costs, nonAEDs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>1879</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1636</ci_lower_limit>
            <ci_upper_limit>2112</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Hospitalizations, All Medical Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>5681</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5257</ci_lower_limit>
            <ci_upper_limit>6077</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Emergency Department Visits, All Medical Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>273</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>251</ci_lower_limit>
            <ci_upper_limit>295</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Outpatient Services, All Medical Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>1021</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>819</ci_lower_limit>
            <ci_upper_limit>1211</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Neurologist Visits, All Medical Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>48</ci_lower_limit>
            <ci_upper_limit>72</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0080</p_value>
            <p_value_desc>Adjusted Cost Differences in Other Healthcare Services, All Medical Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>2555</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>834</ci_lower_limit>
            <ci_upper_limit>4281</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Epilepsy-Related Hospitalizations</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4041</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3776</ci_lower_limit>
            <ci_upper_limit>4305</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Epilepsy-Related Emergency Department Visits</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>105</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97</ci_lower_limit>
            <ci_upper_limit>114</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Epilepsy-Related Outpatient Services</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>384</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>358</ci_lower_limit>
            <ci_upper_limit>413</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Epilepsy-Related Neurologist Visits</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>40</ci_lower_limit>
            <ci_upper_limit>56</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Other Epilepsy-Related Healthcare Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>892</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>584</ci_lower_limit>
            <ci_upper_limit>1192</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Total Healthcare Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>12258</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10482</ci_lower_limit>
            <ci_upper_limit>14083</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Prescription Drug Costs, AEDs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>322</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>245</ci_lower_limit>
            <ci_upper_limit>398</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Prescription Drug Costs, non-AEDs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>841</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>556</ci_lower_limit>
            <ci_upper_limit>1078</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Hospitalizations, All Medical Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3248</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2790</ci_lower_limit>
            <ci_upper_limit>3714</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Emergency Department Visits, All Medical Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>164</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>138</ci_lower_limit>
            <ci_upper_limit>190</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Outpatient Services, All Medical Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>628</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>409</ci_lower_limit>
            <ci_upper_limit>819</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Neurologist Visits, All Medical Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18</ci_lower_limit>
            <ci_upper_limit>42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7628</p_value>
            <p_value_desc>Adjusted Cost Differences in Other Healthcare Services, All Medical Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>235</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1367</ci_lower_limit>
            <ci_upper_limit>1798</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Epilepsy-Related Hospitalizations</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2306</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2016</ci_lower_limit>
            <ci_upper_limit>2603</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Epilepsy-Related Emergency Department Visits</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>52</ci_lower_limit>
            <ci_upper_limit>74</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Epilepsy-Related Outpatient Services</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>211</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>179</ci_lower_limit>
            <ci_upper_limit>245</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Epilepsy-Related Neurologist Visits</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15</ci_lower_limit>
            <ci_upper_limit>33</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0581</p_value>
            <p_value_desc>Adjusted Cost Differences in Other Epilepsy-Related Healthcare Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>277</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19</ci_lower_limit>
            <ci_upper_limit>581</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Total Healthcare Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5437</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3672</ci_lower_limit>
            <ci_upper_limit>7142</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Prescription Drug Costs, AEDs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1019</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>836</ci_lower_limit>
            <ci_upper_limit>1191</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Prescription Drug Costs, Non-AEDs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>1047</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>564</ci_lower_limit>
            <ci_upper_limit>1486</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Hospitalizations</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>9128</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7346</ci_lower_limit>
            <ci_upper_limit>11125</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Emergency Department Visits</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>459</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>326</ci_lower_limit>
            <ci_upper_limit>622</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Outpatient Services</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>2427</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1587</ci_lower_limit>
            <ci_upper_limit>3290</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Neurologists Visits</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>357</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>225</ci_lower_limit>
            <ci_upper_limit>525</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Other Healthcare Services</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>502</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>234</ci_lower_limit>
            <ci_upper_limit>768</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Epilepsy-Related Hospitalizations</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6483</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5329</ci_lower_limit>
            <ci_upper_limit>7927</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Epilepsy-Related Emergency Department Visits</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>150</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>112</ci_lower_limit>
            <ci_upper_limit>199</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Epilepsy-Related Outpatient Services</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>516</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>401</ci_lower_limit>
            <ci_upper_limit>645</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Epilepsy-Related Neurologist Visits</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>158</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97</ci_lower_limit>
            <ci_upper_limit>231</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Other Epilepsy-Related Healthcare Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Ordinary least squares regression was used to adjust differences. Covariates were gender, age, region, comorbidities, baseline treatment, and costs.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>58</ci_lower_limit>
            <ci_upper_limit>113</ci_upper_limit>
            <estimate_desc>Confidence intervals were calculated using a nonparametric bootstrap with 999 replications.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Total Healthcare Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>14582</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12019</ci_lower_limit>
            <ci_upper_limit>17097</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Prescription Drug Costs, AEDs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>420</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>210</ci_lower_limit>
            <ci_upper_limit>630</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Prescription Drug Costs, Non-AEDs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>658</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>217</ci_lower_limit>
            <ci_upper_limit>1131</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Hospitalizations, All Medical Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6040</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3442</ci_lower_limit>
            <ci_upper_limit>8795</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0020</p_value>
            <p_value_desc>Adjusted Cost Differences in Emergency Department Visits, All Medical Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>268</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>81</ci_lower_limit>
            <ci_upper_limit>425</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9670</p_value>
            <p_value_desc>Adjusted Cost Differences in Outpatient Services, All Medical Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-991</ci_lower_limit>
            <ci_upper_limit>944</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2563</p_value>
            <p_value_desc>Adjusted Cost Differences in Neurologist Visits, All Medical Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-77</ci_lower_limit>
            <ci_upper_limit>302</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0100</p_value>
            <p_value_desc>Adjusted Cost Differences in Other Healthcare Services, All Medical Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>328</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>90</ci_lower_limit>
            <ci_upper_limit>588</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Hospitalizations, Epilepsy-Related</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4984</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3168</ci_lower_limit>
            <ci_upper_limit>7335</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Emergency Department Visits, Epilepsy-Related</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>112</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>70</ci_lower_limit>
            <ci_upper_limit>166</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>Adjusted Cost Differences in Outpatient Services, Epilepsy-Related</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>236</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>70</ci_lower_limit>
            <ci_upper_limit>403</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1061</p_value>
            <p_value_desc>Adjusted Cost Differences in Neurologist Visits, Epilepsy-Related</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22</ci_lower_limit>
            <ci_upper_limit>145</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Other Healthcare Services, Epilepsy-Related</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>28</ci_lower_limit>
            <ci_upper_limit>93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted Cost Differences in Total Healthcare Costs</p_value_desc>
            <method>Ordinary Least Squares Regression</method>
            <method_desc>Covariates were gender, age, region, comorbidities, AEDs and non-AEDs known to increase seizure risk and baseline costs.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7673</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4571</ci_lower_limit>
            <ci_upper_limit>10989</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>This is a retrospective study of pre-existing medical record and/or health insurance claims data; all data are de-identified, and thus no assessments of Serious or Non-serious Adverse Events are possible.</desc>
      <group_list>
        <group group_id="E1">
          <title>Medicaid, Uncontrolled, Subgroup</title>
          <description>Database records for participants with 2 or more consecutive changes in anti-epileptic drug (AED) therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or emergency department (ED) visits within the next 365 days. This subgroup was matched with participant records in the Medicaid, well-controlled cohort</description>
        </group>
        <group group_id="E2">
          <title>Medicaid, Well Controlled</title>
          <description>Database records for participants with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits</description>
        </group>
        <group group_id="E3">
          <title>Medicaid, Uncontrolled</title>
          <description>Database records for participants with 2 or more consecutive changes in AED therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visits within the next 365 days. This arm represents all participant records that met the criteria for uncontrolled epilepsy</description>
        </group>
        <group group_id="E4">
          <title>Medicaid, Intermediate</title>
          <description>Database records for participants who are not classified as uncontrolled or well controlled</description>
        </group>
        <group group_id="E5">
          <title>Private, Uncontrolled, Subgroup</title>
          <description>Database records for participants with 2 or more consecutive changes in AED therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visit within the next 365 days. This subgroup was matched with participant records in the private, well-controlled cohort.</description>
        </group>
        <group group_id="E6">
          <title>Private, Well Controlled</title>
          <description>Database records for participants with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visit</description>
        </group>
        <group group_id="E7">
          <title>Private, Uncontrolled</title>
          <description>Database records for participants with 2 or more consecutive changes in AED therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visit within the next 365 days. This arm represents all participant records that met the criteria for uncontrolled epilepsy.</description>
        </group>
        <group group_id="E8">
          <title>Private, Intermediate</title>
          <description>Database records for participants who are not classified as uncontrolled or well controlled</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

